Precision Medicine in Oncology® | Specialty

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Novel STAT3 Inhibitor TT1-101 Is Safe and Shows Antitumor Activity in R/R HCC and Other Solid Tumors

May 9th 2025

The STAT3 inhibitor TT1-101 generated confirmed partial responses among patients with relapsed/refractory HCC and other solid tumors.

FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8th 2025

The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja) for select KRAS-mutated recurrent low-grade serous ovarian cancer.

Dr Shum on the Evolving Treatment Paradigm for EGFR+ NSCLC

May 6th 2025

Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm

May 5th 2025

Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.

Ventana TROP2 (EPR20043) RxDx Device Receives FDA Breakthrough Device Designation for Dato-DXd Selection in NSCLC

May 5th 2025

The AI-driven companion diagnostic device Ventana TROP2 (EPR20043) RxDx has received FDA breakthrough device designation in NSCLC.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors

May 2nd 2025

A priority review was granted to zurletrectinib in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

Dr Paczesny on ST2 as a Biomarker for Acute GVHD Risk Post-Transplant

May 1st 2025

Sophie Paczesny MD, PhD, discussed the ability of ST2 to predict the risk of developing aGVHD or death following transplant.

OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025

May 1st 2025

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Early ctDNA Clearance Is Associated With Response to Daraxonrasib in RAS-Mutant NSCLC

April 28th 2025

Early complete clearance of ctDNA was linked with clinical responses to daraxonrasib in RAS-mutant advanced non–small cell lung cancer.

Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity

April 27th 2025

Olaparib plus pembrolizumab was safe and effective in HRR gene–mutated and/or HRD-positive advanced tumors.

Dr Herzberg on Future Research Directions in KRAS-Mutant NSCLC

April 25th 2025

Benjamin Herzberg, MD, discusses unanswered questions regarding the role of KRAS inhibitors for patients with non–small cell lung cancer.

Dr Dumbrava on Targeting TP53 Y220C Mutations in Solid Tumors With Rezatapopt

April 23rd 2025

Ecaterina Dumbrava, MD, discusses early findings of rezatapopt in patients with solid tumors harboring TP53 Y220C mutations.

Mutational Sequencing Evolutions Drive Precision Medicine Approaches for AML

April 22nd 2025

Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.

China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors

April 21st 2025

China’s NMPA has accepted an sNDA for review, seeking the approval of repotrectinib for advanced solid tumors harboring NTRK fusions.

Five Under 5: Top Oncology Videos for the Week of 4/13

April 20th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

NDA Accepted in China for Zurletrectinib for NTRK Gene Fusion+ Advanced Solid Tumors

April 16th 2025

A new drug application for zurletrectinib has been accepted in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

Five Under 5: Top Oncology Videos for the Week of 4/6

April 13th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 4/6

April 12th 2025

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.